Register Login

Abiopharma

  • Home
  • About
  • Newsroom
    • News
    • Company List
  • Events
  • Automated Tools
  • Contact

News list

Alterity Therapeutics Limited (ATHE)

  • Business News
  • June 23, 2025, 02:30 UTC
  • 0

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

Market reaction Comment Full text

Immutep Limited (IMMP)

  • Business News
  • June 23, 2025, 01:49 UTC
  • 0

Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases

Market reaction Comment Full text

Cordlife Group Limited (P8A)

  • Business News
  • June 22, 2025, 23:35 UTC
  • 0

Cordlife To Hold Townhalls For affected Clients In Singapore; Explores Improvements To Proposal For Affected Customers

Market reaction Comment Full text

Cordlife Group Limited (P8A)

  • SEC News
  • June 22, 2025, 23:35 UTC
  • 0

General Announcement: Townhall Meetings to be held from 23 June 2025 to 25 June 2025 and Press Release

Comment Full text

Cordlife Group Limited (P8A)

  • Business News
  • June 22, 2025, 23:35 UTC
  • 0

Townhall Meetings to be held from 23 June 2025 to 25 June 2025 and Press Release

Market reaction Comment Full text

Exelixis Inc (EXEL)

  • Business News
  • June 22, 2025, 21:01 UTC
  • 0

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

Market reaction Comment Full text

Molecular Partners AG (MOLN)

  • Business News
  • June 22, 2025, 20:00 UTC
  • 0

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025

Market reaction Comment Full text

Novo Nordisk (NVO)

  • Business News
  • June 22, 2025, 19:39 UTC
  • 0

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress

Market reaction Comment Full text

Eli Lilly and Company (LLY)

  • Business News
  • June 22, 2025, 18:32 UTC
  • 0

Lillys once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Market reaction Comment Full text

Quipt Home Medical Corp (QIPT)

  • Business News
  • June 22, 2025, 16:56 UTC
  • 0

QIPT Investors Have Opportunity to Join Quipt Home Medical Corp. Fraud Investigation with the Schall Law Firm

Market reaction Comment Full text

Rocket Pharmaceuticals Inc (RCKT)

  • Business News
  • June 22, 2025, 16:50 UTC
  • 0

RCKT INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Market reaction Comment Full text

Aoxin Q & M Dental Grp Limited (1D4)

  • SEC News
  • June 22, 2025, 15:58 UTC
  • 0

General Announcement: Refund Of Excess Claim of Cost Of Material For FY2024

Comment Full text

Fulgent Genetics Inc (FLGT)

  • Business News
  • June 22, 2025, 14:00 UTC
  • 0

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT

Market reaction Comment Full text

PepGen Inc. (PEPG)

  • Business News
  • June 22, 2025, 14:00 UTC
  • 0

Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG

Market reaction Comment Full text

Novo Nordisk (NVO)

  • Business News
  • June 22, 2025, 13:04 UTC
  • 0

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Market reaction Comment Full text
  • 1
  • 2
  • 3
  • Next

Search

News categories

  • Technical Exchange News(9375)
  • Event(407)
  • SEC News(153224)
  • FDA Approval(8741)
  • Company Report(721)
  • Business News(104528)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin